卡尔维斯塔制药公司获得了"买入"评级和42美元的目标价格. KalVista Pharmaceuticals receives a 'buy' rating and $42 price target from Stifel Nicolaus.

卡尔维斯塔制药公司 (NASDAQ:KALV) 在Stifel Nicolaus的"买入"评级下,新目标价为42.00美元,而其他分析师则将其目标提高到28至36美元之间. KalVista Pharmaceuticals (NASDAQ:KALV) has received a "buy" rating from Stifel Nicolaus with a new price target of $42.00, while other analysts have raised their targets to between $28.00 and $36.00. 临床阶段的生物技术专注于治疗罕见疾病的蛋白酶抑制剂,报告了强的财务势头和机构所有权的增加. The clinical-stage biotech, focused on protease inhibitors for rare diseases, reported strong financial momentum and has seen an increase in institutional ownership.